SCHEMBL3726229

SCHEMBL3726229

O=C(Cn1c(=O)[nH]c2ccccc21)N1CCN(c2ccccc2-c2cnc(N3CCOCC3)nc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 4/20 0.60
KCNH2 Q12809 2/20 0.60
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 2/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
HSD17B10 Q99714 1/20 0.46
GRIN2B Q13224 5/20 0.44
GRIN1 Q05586 3/20 0.44
TSHR P16473 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 2/20 0.41
HTR7 P34969 2/20 0.40
USP2 O75604 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CNR2 P34972 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3732635 0.91 CXCR3 (0.59) CXCR3KCNH2KDM4EALDH1A1HPGD
SCHEMBL163879 0.84 CXCR3 (0.62) CXCR3KCNH2KDM4EALDH1A1HPGD
SCHEMBL3736567 0.83 CXCR3 (0.52) CXCR3KCNH2SMN1; SMN2MAPTHTR7
SCHEMBL166876 0.82 CXCR3 (0.59) CXCR3KCNH2GRIN2BGRIN1TSHR
SCHEMBL167757 0.80 CXCR3 (0.73) CXCR3KCNH2KDM4EALDH1A1HPGD
SCHEMBL114084 0.80 ALDH1A1 (0.41) CXCR3KCNH2KDM4EALDH1A1HPGD
SCHEMBL164210 0.78 CXCR3 (0.60) CXCR3KCNH2KDM4EALDH1A1HPGD
SCHEMBL165175 0.77 CXCR3 (0.62) CXCR3KCNH2
SCHEMBL168189 0.77 CXCR3 (0.54) CXCR3KCNH2GRIN2BGRIN1SMN1; SMN2
SCHEMBL3726632 0.76 CXCR3 (0.52) CXCR3KCNH2GRIN2BGRIN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US claimed
EP-2424840-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-08-06 EP disclosed
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
WO-2010126811-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 WO disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 CXCR3 1/4885KCNH2 1561/4885KDM4E 3994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.